AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Interleukin-10 receptor subunit alpha including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Interleukin-10 receptor subunit alpha therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Interleukin-10 receptor subunit alpha, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Interleukin-10 receptor subunit alpha. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Interleukin-10 receptor subunit alpha. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Interleukin-10 receptor subunit alpha includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Interleukin-10 receptor subunit alpha
partner:
Reaxense
upacc:
Q13651
UPID:
I10R1_HUMAN
Alternative names:
CDw210a; Interleukin-10 receptor subunit 1
Alternative UPACC:
Q13651; A8K6I0; B0YJ27
Background:
Interleukin-10 receptor subunit alpha (IL10RA), also known as CDw210a, plays a pivotal role in immune regulation. As a cell surface receptor for cytokine IL10, it initiates anti-inflammatory functions by limiting tissue disruption during inflammation. The binding of IL10 to IL10RA induces a conformational change, facilitating the assembly of a complex that activates kinases JAK1 and TYK2. These kinases phosphorylate IL10RA, leading to STAT3 activation and the expression of anti-inflammatory genes.
Therapeutic significance:
IL10RA's involvement in Inflammatory bowel disease 28, an autosomal recessive condition characterized by chronic inflammation of the gastrointestinal tract, underscores its therapeutic potential. Targeting IL10RA could offer new strategies for managing Crohn's disease and ulcerative colitis, conditions marked by excessive inflammation. Understanding IL10RA's role could open doors to innovative treatments that modulate the immune response in these debilitating diseases.
